Hey, it's Kramer, and this is my morning take on the market from today's CNBC Investing Club morning meeting. Let's talk Bristol next, not exactly as clear cut of a body like we're saying with Dover. They did beat though. It was a good quarter. They beat on REVs, they beat on earnings. They raised a full year out. But they beat on old drugs that I didn't want. I wanted it on new drugs.

Yeah, Revlimid was a source of the beat.

They're at the higher end of the range now.

Currency, now having a positive impact, too.

$500 million more in sales of the legacy portfolio, $250 more on the growth portfolio.

Kovenfi was a beat, $27 million, looking for around 17 million, but there was a 9 million

benefit to sale.

So people are kind of backing that out and saying not as big of a beat as they would have

hoped.

They did talk about the trial miss that we talked about yesterday for adjunctive schizophrenia. They're kind of downplaying it. Yes, they are. Amazingly.

They're pulling out 70 to 80% of the schizophrenia market is monotherapy, so no real risk there.

And they don't think the arise, that's the name of the trial, impacts how they're thinking about

Alzheimer's disease, psychosis later this year. And I know, look, I've got to tell you,

I have no tolerance for

companies that screw up

like this and wasn't screw up.

Their level of confidence

is shocking to me.

Yeah.

And they seem like good people.

So I come back and say, this does not feel like Dan heard to me where I've totally lost confidence. It does not feel like GE healthcare where I completely lost confidence. Constellation Brands, where it's just totally lost confidence. So I want to wait and see. Otherwise, I'm not averse to kicking out something if I thought it was bad. We sold something up here. Sure. Look, I mean's cheap. It pays a big dividend. And because the multiple is so low, if you get any bit of good news, you could really fly. Absolutely. But again, kind of like we were saying yesterday with Kobenfi, it's a show me story now. Start your day with my outlook on the market every morning. visit cbbc.com slash morning take to become a CNBC investing club member at a special rate today.

All opinions expressed by Jim Kramer on this podcast and in connection with the CNBC investing club are solely Kramer's opinions and do not reflect the opinions of

...